MedTrace Logo

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2011-01-11

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Risedronate

DRUG

Raloxifene

OTHER

Placebo

Sponsors & Collaborators

Principal Investigators

  • Tara Semanchik · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2004-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790101 on ClinicalTrials.gov